Cargando…
Esophago-tracheobronchial fistula following treatment of anlotinib in advanced squamous cell lung cancer: Two case reports
RATIONALE: Anlotinib, a novel orally administered multitargeted tyrosine kinase inhibitor, inhibiting tumor angiogenesis and growth, significantly prolonged overall survival, and progression-free survival with a manageable safety profile as a third-line therapy among refractory advanced nonsmall cel...
Autores principales: | Zhang, Pin-Liang, Liu, Zeng-Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946411/ https://www.ncbi.nlm.nih.gov/pubmed/31689797 http://dx.doi.org/10.1097/MD.0000000000017700 |
Ejemplares similares
-
A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma
por: Tang, Yong, et al.
Publicado: (2019) -
Advanced intrahepatic cholangiocarcinoma treated using anlotinib and microwave ablation: A case report
por: Zhang, Aixia, et al.
Publicado: (2019) -
Predictive value of microvascular density for response to anlotinib in advanced NSCLC
por: Liu, Danqing, et al.
Publicado: (2022) -
Carrelizumab combined with anlotinib in the treatment of extensive-stage small cell lung cancer: A case report
por: Liu, Liang, et al.
Publicado: (2021) -
Endobronchial lipoma with tracheobronchial aspergillosis: A case report
por: Wang, Yuanyuan, et al.
Publicado: (2021)